These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7995185)

  • 1. Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.
    Clerici C; Gentili G; Boschetti E; Santucci C; Aburbeh AG; Natalini B; Pellicciari R; Morelli A
    Dig Dis Sci; 1994 Dec; 39(12):2601-6. PubMed ID: 7995185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
    Pellicciari R; Garzon-Aburbeh A; Natalini B; Marinozzi M; Clerici C; Gentili G; Morelli A
    J Med Chem; 1993 Dec; 36(26):4201-7. PubMed ID: 8277502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
    Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
    Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
    Jung YJ; Lee JS; Kim YM
    J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
    Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
    J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
    Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
    Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid.
    Jung YJ; Lee JS; Kim YM
    J Pharm Sci; 2001 Nov; 90(11):1767-75. PubMed ID: 11745734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and properties of N,N'-bis(5-aminosalicyl)-L-cystine as a colon-specific deliverer of 5-aminosalicylic acid and cystine.
    Kim H; Kim D; Choi D; Jeon H; Han J; Jung Y; Kong H; Kim YM
    Drug Deliv; 2008 Jan; 15(1):37-42. PubMed ID: 18197522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid.
    Jung YJ; Kim HH; Kong HS; Kim YM
    Arch Pharm Res; 2003 Apr; 26(4):264-9. PubMed ID: 12735682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.
    Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Rasmussen SN; Hansen SH
    Dig Dis Sci; 1993 Oct; 38(10):1831-6. PubMed ID: 8104772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid.
    Jung YJ; Lee JS; Kim HH; Kim YM; Han SK
    Arch Pharm Res; 1998 Apr; 21(2):174-8. PubMed ID: 9875427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE; Rose GM; Conklin JD
    J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N,N'-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis.
    Kim H; Huh J; Jeon H; Choi D; Han J; Kim Y; Jung Y
    J Pharm Sci; 2009 Jan; 98(1):159-68. PubMed ID: 18399548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
    Tolia V; Massoud N; Klotz U
    J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):333-8. PubMed ID: 2565380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
    Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
    Kovács A
    Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
    Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
    Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses.
    Knoll U; Strauhs P; Schusser G; Ungemach FR
    J Vet Pharmacol Ther; 2002 Apr; 25(2):135-43. PubMed ID: 12000534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.